Quarterly ResultJul 27, 2026, 04:47 PM
Champions Oncology FY26 Revenue $59.4M; Net Loss $1.2M
AI Summary
Champions Oncology, Inc. reported fiscal year 2026 revenue of approximately $59.4 million, a 4% increase year-over-year, alongside a net loss of $1.2 million and an accumulated deficit of $81.1 million. The company utilized $4.5 million in cash from operations and held a cash balance of $4.9 million. Champions Oncology is a technology-enabled research organization focused on oncology drug discovery and development, leveraging its proprietary PDX models and Datacenter across research services, SaaS, and drug discovery business lines. The company increased its R&D spending to $9.1 million and believes it has sufficient capital to fund operations through at least August 2027.
Key Highlights
- Fiscal year 2026 revenue totaled approximately $59.4 million, a 4% increase from the previous year.
- Reported a net loss of approximately $1.2 million for fiscal year 2026.
- Accumulated deficit reached approximately $81.1 million.
- Cash balance stood at $4.9 million as of April 30, 2026.
- Used approximately $4.5 million in cash from operations for the twelve months ending April 30, 2026.
- Research and development expenses increased to $9.1 million in 2026 from $6.8 million in 2025.
- Company believes current cash and operations will fund activities through at least August 2027.
- Research services revenue has grown at an average annual rate of 12% since 2019.
Price Impact
More from CSBR